GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anacor Pharmaceuticals Inc (NAS:ANAC) » Definitions » ROE %

Anacor Pharmaceuticals (Anacor Pharmaceuticals) ROE % : -133.34% (As of Mar. 2016)


View and export this data going back to 2010. Start your Free Trial

What is Anacor Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Anacor Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2016 was $-64.59 Mil. Anacor Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Mar. 2016 was $48.44 Mil. Therefore, Anacor Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2016 was -133.34%.

The historical rank and industry rank for Anacor Pharmaceuticals's ROE % or its related term are showing as below:

ANAC's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.1
* Ranked among companies with meaningful ROE % only.

Anacor Pharmaceuticals ROE % Historical Data

The historical data trend for Anacor Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anacor Pharmaceuticals ROE % Chart

Anacor Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -136.41 -599.54 134.29 -87.03 -93.42

Anacor Pharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.48 -76.57 -106.91 -140.02 -133.34

Competitive Comparison of Anacor Pharmaceuticals's ROE %

For the Biotechnology subindustry, Anacor Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anacor Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anacor Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Anacor Pharmaceuticals's ROE % falls into.



Anacor Pharmaceuticals ROE % Calculation

Anacor Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2015 is calculated as

ROE %=Net Income (A: Dec. 2015 )/( (Total Stockholders Equity (A: Dec. 2014 )+Total Stockholders Equity (A: Dec. 2015 ))/ count )
=-61.248/( (78.832+52.29)/ 2 )
=-61.248/65.561
=-93.42 %

Anacor Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2016 is calculated as

ROE %=Net Income (Q: Mar. 2016 )/( (Total Stockholders Equity (Q: Dec. 2015 )+Total Stockholders Equity (Q: Mar. 2016 ))/ count )
=-64.588/( (52.29+44.584)/ 2 )
=-64.588/48.437
=-133.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2016) net income data. ROE % is displayed in the 30-year financial page.


Anacor Pharmaceuticals  (NAS:ANAC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2016 )
=Net Income/Total Stockholders Equity
=-64.588/48.437
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-64.588 / 70.14)*(70.14 / 170.052)*(170.052 / 48.437)
=Net Margin %*Asset Turnover*Equity Multiplier
=-92.08 %*0.4125*3.5108
=ROA %*Equity Multiplier
=-37.98 %*3.5108
=-133.34 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2016 )
=Net Income/Total Stockholders Equity
=-64.588/48.437
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-64.588 / -64.588) * (-64.588 / -59.684) * (-59.684 / 70.14) * (70.14 / 170.052) * (170.052 / 48.437)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0822 * -85.09 % * 0.4125 * 3.5108
=-133.34 %

Note: The net income data used here is four times the quarterly (Mar. 2016) net income data. The Revenue data used here is four times the quarterly (Mar. 2016) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Anacor Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Anacor Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anacor Pharmaceuticals (Anacor Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.
Executives
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anders D Hove director 30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
Graeme Bell officer: Executive VP and CFO 1324 WAVERLY ROAD, GLADWYNE PA 19035
Ryan T Sullivan officer: EVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Paul L Berns director, officer: President and CEO 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Mark Leschly director RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019
Geoffrey M. Parker officer: Executive Vice President & CFO 15 RIORDAN PLACE, MENLO PARK CA 94025
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
David P Perry director, officer: President and CEO 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Rho Management Ventures Iv Llc 10 percent owner 124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Qp Lp 10 percent owner 124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Lp 10 percent owner 124 DUNE ROAD, QUOGUE NY 11959

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Headlines